Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 1/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL100765 | 0.68 | HPGDS (0.46) | HPGDSLTA4HPIN1BRD4 | |
| SCHEMBL3953551 | 0.68 | HPGDS (0.38) | HPGDSLTA4HBRD4 | |
| SCHEMBL611280 | 0.67 | HPGDS (0.41) | HPGDSLTA4HPIN1BRD4 | |
| SCHEMBL4435262 | 0.65 | HPGDS (0.33) | HPGDSLTA4H | |
| SCHEMBL7183288 | 0.65 | HPGDS (0.36) | HPGDSLTA4HBRD4 | |
| SCHEMBL7376054 | 0.65 | HPGDS (0.40) | HPGDSLTA4HBRD4 | |
| SCHEMBL1115187 | 0.65 | HPGDS (0.43) | HPGDSLTA4HPIN1BRD4 | |
| SCHEMBL722557 | 0.65 | LTA4H (0.64) | HPGDSLTA4HBRD4 | |
| SCHEMBL28177563 | 0.64 | LTA4H (0.45) | HPGDSLTA4HBRD4 | |
| SCHEMBL9464782 | 0.64 | HPGDS (0.38) | HPGDSLTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0170498-B1 | N-ACETONYL-SUBSTITUTED-AMIDES, COMPOSITIONS CONTAINING THEM AND THEIR USE IN COMBATING FUNGI | ROHM AND HAAS COMPANY (US) | 1991-09-11 | — | — | EP | claimed |
| US-20090170897-A1 | Method of Treating Neuropathic Pain | PFIZER, INC. (US) | 2009-07-02 | — | — | US | disclosed |
| EP-2074110-A1 | HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5HT6 RECEPTOR | Abbott GmbH & Co. KG (DE) | 2009-07-01 | — | — | EP | disclosed |
| WO-2007118900-A1 | HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5HT6 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2007-10-25 | — | — | WO | disclosed |
| US-20070197587-A1 | Quinoline Derivatives as CRTH2 Antagonists | PFIZER INC | 2007-08-23 | — | — | US | disclosed |
| US-7220760-B2 | Quinoline derivatives as CRTH2 antagonists | PFIZER INC. (US) | 2007-05-22 | — | — | US | disclosed |
| EP-1740179-A1 | METHOD OF TREATING NEUROPATHIC PAIN USING A CRTH2 RECEPTOR ANTAGONIST | Pfizer Limited (GB) | 2007-01-10 | — | — | EP | disclosed |
| EP-1556356-B1 | TETRAHYDROQUINOLINE DERIVATIVES AS CRTH2 ANTAGONISTS | WARNER LAMBERT CO (US) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005102338-A1 | METHOD OF TREATING NEUROPATHIC PAIN USING A CRTH2 RECEPTOR ANTAGONIST | PFIZER LIMITED (GB) | 2005-11-03 | — | — | WO | disclosed |
| EP-1556356-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS CRTH2 ANTAGONISTS | Warner-Lambert Company LLC (US) | 2005-07-27 | — | — | EP | disclosed |
| US-20040132772-A1 | 1-carbonyl-4-carbonylaminotetrahydroquinoline derivatives; especially treating asthma and allergic rhinitis | WARNER-LAMBERT COMPANY LLC | 2004-07-08 | — | — | US | disclosed |
| EP-1435356-A1 | Quinoline derivatives as CRTH2 antagonists | Warner-Lambert Company LLC (US) | 2004-07-07 | — | — | EP | disclosed |
| WO-2004035543-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS CRTH2 ANTAGONISTS | WARNER-LAMBERT COMPANY LLC (US) | 2004-04-29 | — | — | WO | disclosed |
| EP-1413306-A1 | Tetrahydroquinoline derivatives as CRTH2 antagonists | Warner-Lambert Company LLC (US) | 2004-04-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132772-A1 | 1-carbonyl-4-carbonylaminotetrahydroquinoline derivatives; especially treating asthma and allergic rhinitis | HRH1, HRH2, HRH4 | HPGDS 2285/4885LTA4H 95/4885PIN1 3658/4885 |
| US-20070197587-A1 | Quinoline Derivatives as CRTH2 Antagonists | HRH2, HRH1, HRH3 | HPGDS 2456/4885LTA4H 334/4885PIN1 3488/4885 |
| US-20090170897-A1 | Method of Treating Neuropathic Pain | OPRL1, CNR2, HRH2 | HPGDS 862/4885LTA4H 55/4885PIN1 884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.